NERVGEN PHARMA CORP (NGEN.CA) Stock Fundamental Analysis
Canada - TSX Venture Exchange - TSX-V:NGEN - CA64082X2032 - Common Stock
7.21 CAD
-0.1 (-1.37%)
Overall NGEN gets a fundamental rating of 1 out of 10. We evaluated NGEN against 33 industry peers in the Pharmaceuticals industry. NGEN has a bad profitability rating. Also its financial health evaluation is rather negative. NGEN is valued expensive and it does not seem to be growing.
1. Profitability
1.1 Basic Checks
- In the past year NGEN has reported negative net income.
- In the past year NGEN has reported a negative cash flow from operations.
- NGEN had negative earnings in each of the past 5 years.
- NGEN had a negative operating cash flow in each of the past 5 years.
1.2 Ratios
- The Return On Assets of NGEN (-197.42%) is worse than 87.88% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | -197.42% | ||
| ROE | N/A | ||
| ROIC | N/A |
ROA(3y)N/A
ROA(5y)N/A
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
1.3 Margins
- NGEN does not have Profit Margin and Operating Margin and Gross Margin available, so we won't be analyzing them here.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| OM | N/A | ||
| PM (TTM) | N/A | ||
| GM | N/A |
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
2. Health
2.1 Basic Checks
- There is no outstanding debt for NGEN. This means it has a Debt/Equity and Debt/FCF ratio of 0 and it is amongst the best of the sector and industry.
2.2 Solvency
- An Altman-Z score of 3.12 indicates that NGEN is not in any danger for bankruptcy at the moment.
- The Altman-Z score of NGEN (3.12) is better than 90.91% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | N/A | ||
| Debt/FCF | N/A | ||
| Altman-Z | 3.12 |
ROIC/WACCN/A
WACCN/A
2.3 Liquidity
- A Current Ratio of 0.79 indicates that NGEN may have some problems paying its short term obligations.
- With a Current ratio value of 0.79, NGEN is not doing good in the industry: 87.88% of the companies in the same industry are doing better.
- NGEN has a Quick Ratio of 0.79. This is a bad value and indicates that NGEN is not financially healthy enough and could expect problems in meeting its short term obligations.
- With a Quick ratio value of 0.79, NGEN is not doing good in the industry: 72.73% of the companies in the same industry are doing better.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Current Ratio | 0.79 | ||
| Quick Ratio | 0.79 |
3. Growth
3.1 Past
- NGEN shows a small growth in Earnings Per Share. In the last year, the EPS has grown by 2.11%.
EPS 1Y (TTM)2.11%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%14.29%
Revenue 1Y (TTM)N/A
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%N/A
3.2 Future
- The Earnings Per Share is expected to grow by 50.70% on average over the next years. This is a very strong growth
- No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
EPS Next Y6.7%
EPS Next 2Y7.18%
EPS Next 3Y8.54%
EPS Next 5Y50.7%
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A
3.3 Evolution
- No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
4. Valuation
4.1 Price/Earnings Ratio
- NGEN reported negative earnings for the last year, which makes the Price/Earnings Ratio negative.
- Also next year NGEN is expected to report negative earnings again, which makes the also the Forward Price/Earnings Ratio negative.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | N/A | ||
| Fwd PE | N/A |
4.2 Price Multiples
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| P/FCF | N/A | ||
| EV/EBITDA | N/A |
4.3 Compensation for Growth
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y7.18%
EPS Next 3Y8.54%
5. Dividend
5.1 Amount
- NGEN does not give a dividend.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | 0% |
TSX-V:NGEN (1/20/2026, 7:00:00 PM)
7.21
-0.1 (-1.37%)
Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryPharmaceuticals
Earnings (Last)11-24 2025-11-24/bmo
Earnings (Next)04-01 2026-04-01
Inst Owners0.06%
Inst Owner ChangeN/A
Ins Owners2.77%
Ins Owner ChangeN/A
Market Cap530.37M
Revenue(TTM)N/A
Net Income(TTM)-25.82M
Analysts80
Price Target7.75 (7.49%)
Short Float %N/A
Short RatioN/A
Dividend
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | 0% |
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)1
Avg EPS beat(2)-78.22%
Min EPS beat(2)-157.43%
Max EPS beat(2)0.99%
EPS beat(4)2
Avg EPS beat(4)-43.47%
Min EPS beat(4)-157.43%
Max EPS beat(4)33.99%
EPS beat(8)N/A
Avg EPS beat(8)N/A
EPS beat(12)N/A
Avg EPS beat(12)N/A
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)N/A
Avg Revenue beat(2)N/A
Min Revenue beat(2)N/A
Max Revenue beat(2)N/A
Revenue beat(4)N/A
Avg Revenue beat(4)N/A
Min Revenue beat(4)N/A
Max Revenue beat(4)N/A
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)7.04%
PT rev (3m)7.04%
EPS NQ rev (1m)0%
EPS NQ rev (3m)0%
EPS NY rev (1m)11.01%
EPS NY rev (3m)14.16%
Revenue NQ rev (1m)N/A
Revenue NQ rev (3m)N/A
Revenue NY rev (1m)N/A
Revenue NY rev (3m)N/A
Valuation
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | N/A | ||
| Fwd PE | N/A | ||
| P/S | N/A | ||
| P/FCF | N/A | ||
| P/OCF | N/A | ||
| P/B | N/A | ||
| P/tB | N/A | ||
| EV/EBITDA | N/A |
EPS(TTM)-0.38
EYN/A
EPS(NY)-0.3
Fwd EYN/A
FCF(TTM)-0.23
FCFYN/A
OCF(TTM)-0.23
OCFYN/A
SpS0
BVpS-0.04
TBVpS-0.05
PEG (NY)N/A
PEG (5Y)N/A
Graham NumberN/A
Profitability
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | -197.42% | ||
| ROE | N/A | ||
| ROCE | N/A | ||
| ROIC | N/A | ||
| ROICexc | N/A | ||
| ROICexgc | N/A | ||
| OM | N/A | ||
| PM (TTM) | N/A | ||
| GM | N/A | ||
| FCFM | N/A |
ROA(3y)N/A
ROA(5y)N/A
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexgc growth 3YN/A
ROICexgc growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-Score4
Asset Turnover0
Health
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | N/A | ||
| Debt/FCF | N/A | ||
| Debt/EBITDA | N/A | ||
| Cap/Depr | N/A | ||
| Cap/Sales | N/A | ||
| Interest Coverage | N/A | ||
| Cash Conversion | N/A | ||
| Profit Quality | N/A | ||
| Current Ratio | 0.79 | ||
| Quick Ratio | 0.79 | ||
| Altman-Z | 3.12 |
F-Score4
WACCN/A
ROIC/WACCN/A
Cap/Depr(3y)38.62%
Cap/Depr(5y)46.06%
Cap/Sales(3y)N/A
Cap/Sales(5y)N/A
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)2.11%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%14.29%
EPS Next Y6.7%
EPS Next 2Y7.18%
EPS Next 3Y8.54%
EPS Next 5Y50.7%
Revenue 1Y (TTM)N/A
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%N/A
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A
EBIT growth 1Y-10.78%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year63.5%
EBIT Next 3YN/A
EBIT Next 5YN/A
FCF growth 1Y-25.04%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y-26.38%
OCF growth 3YN/A
OCF growth 5YN/A
NERVGEN PHARMA CORP / NGEN.CA FAQ
What is the ChartMill fundamental rating of NERVGEN PHARMA CORP (NGEN.CA) stock?
ChartMill assigns a fundamental rating of 1 / 10 to NGEN.CA.
What is the valuation status of NERVGEN PHARMA CORP (NGEN.CA) stock?
ChartMill assigns a valuation rating of 0 / 10 to NERVGEN PHARMA CORP (NGEN.CA). This can be considered as Overvalued.
What is the profitability of NGEN stock?
NERVGEN PHARMA CORP (NGEN.CA) has a profitability rating of 0 / 10.
What is the expected EPS growth for NERVGEN PHARMA CORP (NGEN.CA) stock?
The Earnings per Share (EPS) of NERVGEN PHARMA CORP (NGEN.CA) is expected to grow by 6.7% in the next year.